There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX) and Ampliphi Biosciences (APHB) with bullish sentiments.
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Neurocrine today and set a price target of $102. The company’s shares closed yesterday at $85.05.
“Our price target of $102/share is based on an equally weighted composite of: (a) $103/share, as a 35x multiple of taxed and diluted FY25 GAAP EPS of $8.80 discounted back to and (b) an NPV of $101/share (discount rate 10%, growth rate 2%). We base our valuation on a 20% royalty on sales for Elagolix in endometriosis and uterine fibrosis (probability adjusted). For valbenazine, we include the indication of TD. For opicapone, we include the US revenue (63% goes to 85% POS.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.4% and a 45.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $110.20, representing a 29.6% upside. In a report issued on January 7, Cantor Fitzgerald also maintained a Buy rating on the stock with a $121 price target.
See today’s analyst top recommended stocks >>
Ampliphi Biosciences (APHB)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ampliphi Biosciences today and set a price target of $3.50. The company’s shares closed yesterday at $0.27, close to its 52-week low of $0.15.
“Valuation and risks to price target achievement. We reiterate our Buy rating and price target of $3.50. We project the following in our clinical NPV model for S. aureus: (1) projected launch in 2021 for bacteremia with a 15% chance of success and $300 million in peak sales; and (2) projected launch in 2022 for prosthetic joint infections with a 10% chance of success and $200 million in peak sales.”
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -20.9% and a 22.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.
Ampliphi Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.